NCT06006650View on ClinicalTrials.gov

Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell

PHASE2RecruitingINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

December 31, 2031

Study Completion Date

December 31, 2031

Conditions
NeoadjuventPD-1 InhibitorChemotherapyEsophageal Squamous Cell Carcinoma
Interventions
DRUG

Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin

Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin

Trial Locations (3)

710038

RECRUITING

Tangdu Hospital of the Fourth Millitary Medical University, Xi'an

RECRUITING

Hongtao Duan, Xi’an

RECRUITING

Tangdu Hospital, the Air Force Military University, Xi'an

All Listed Sponsors
lead

Tang-Du Hospital

OTHER

NCT06006650 - Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell | Biotech Hunter | Biotech Hunter